Amoy Diagnostics Co. Ltd. News - Recent Updates & Announcements

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

Amoy Diagnostics Co. Ltd.

In News

AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology - News-Medical

Application of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis - Rao - 2023 - Cancer Medicine - Wiley Online Library

Hemato Oncology Testing Market Size to Hit USD 15.72 Billion by 2034 - BioSpace

Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer | Scientific Reports - Nature

Companion Diagnostics Market size is set to grow by USD 28.98 billion from 2024-2028, Rising use of personalized medicine to boost the market growth, Technavio - PR Newswire

Molecular Diagnostics Market worth $30.74 billion by 2030 - MarketsandMarkets

AmoyDx® Pan Lung Cancer PCR Panel approved in Japan as a companion diagnostic for Haiyitan® tablets (gumarontinib) - News-Medical

Global In-Vitro Diagnostics Market Predicted to Surpass the USD 90 Billion Mark by 2032 | DelveInsight - GlobeNewswire

Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study - Nature

Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance - Nature

Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions - Nature